UroGen 10-Q: Q3 Revenue $89.0M, Net Loss Narrows to $1.5M, $90.5M Cash
URGN sits 92% above its 52-week low of $16.5.
Summary
UroGen's Q3 2026 10-Q shows revenue of $89.0M (Zusduri $68.0M) and a net loss of just $1.5M, with $90.5M in cash and securities and management guiding to more than a year of runway.
Key Events · Earnings and Guidance · URGN
-
Q3 Revenue Jumps to $89.0M
Revenue was $89.0M versus $27.5M a year earlier, driven by $68.0M of Zusduri sales against $1.8M in the prior-year quarter.
-
Net Loss Narrows to $1.5M
Operating income of $8.3M versus a $27.4M operating loss last year; nine-month net loss fell to $39.4M from $127.1M.
-
Jelmyto Sales Decline
Jelmyto revenue fell to $21.0M in Q3 2026 from $25.7M a year earlier, and to $64.7M for the nine months from $70.2M.
-
$90.5M Cash, Runway Beyond a Year
Cash, equivalents and marketable securities totaled $90.5M at September 30, 2026; management states this funds operations beyond one year from issuance with no going-concern qualification.
Analysis · URGN · Life Sciences
The quarter is the story: Zusduri sales of $68.0M drove total revenue to $89.0M versus $27.5M a year ago, and the company posted operating income of $8.3M against a $27.4M operating loss last year. Net loss shrank to $1.5M from $33.3M. That is close to breakeven on a GAAP basis, which changes the funding conversation — management now says $90.5M of cash and securities funds operations beyond a year from issuance, with no going-concern qualification. The offset is Jelmyto, which fell to $21.0M from $25.7M, so the growth is entirely one product ramping while the legacy product erodes. Debt is heavy: $189.4M carrying value on the Pharmakon term loan at 8.25% fixed, with $13.9M of interest expense in the first nine months. Two directors also adopted 10b5-1 plans in late August covering up to 50,000 and 120,000 shares.
How filings like this one have moved
In the 30 days to Nov 4, 2026, 41.4% of the 1207 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, URGN was trading at $31.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $16.50 to $50.81. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.